Use of fibrin sealant to reduce bloody drainage and hemoglobin loss after total knee arthroplasty: a brief note on a randomized prospective trial.
BACKGROUND
A phase-III trial that included fifty-three patients undergoing unilateral primary total knee arthroplasty with cement was conducted to investigate the hemostatic efficacy of fibrin sealant.


METHODS
Following cementing of the joint, 10 mL of fibrin sealant was sprayed onto the wound before tourniquet deflation and wound closure. No placebo was used in the control group. All patients received drains.


RESULTS
Within twelve hours after the surgery, the amount of bloody drainage was 184.5 +/- 28.9 mL (mean and standard error) in the fibrin-sealant group (information available for twenty-three patients) and 408.3 +/- 54.6 mL in the control group (information available for twenty-three patients) (p = 0.002, after adjustment for variance in the time that the drainage was measured). On the first postoperative day, the hemoglobin level had decreased by 20.1 +/- 2.1 g/L in the fibrin-sealant group (information available for twenty-two patients) and by 27.3 +/- 2.1 g/L in the control group (information available for twenty-four patients). After adjustment for baseline values, the decrease in the hemoglobin level was 28.9% less in the fibrin-sealant group than in the control group (p = 0.005, 95% confidence limits = 10.2, 43.7). There were no seroconversions in the fibrin-sealant group.


CONCLUSIONS
These results suggest that fibrin sealant can safely reduce bloody drainage following total knee arthroplasty while maintaining higher hemoglobin levels.
Wang
G J
GJ
University of Virginia Health System, Charlottesville 22908, USA. uvatac@virginia.edu
Hungerford
D S
DS
Savory
C G
CG
Rosenberg
A G
AG
Mont
M A
MA
Burks
S G
SG
Mayers
S L
SL
Spotnitz
W D
WD
D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D004322:Drainage; D015718:Fibrin Tissue Adhesive / Q000627:therapeutic use*; D006454:Hemoglobins / Q000172:deficiency*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D011446:Prospective Studies; D016037:Single-Blind Method
D015718:Fibrin Tissue Adhesive; D006454:Hemoglobins; D006490:Hemostatics